Koji Tamada

USPTO Granted Patents = 22 (Patent Applications = 14)

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 90(Granted Patents)

Location History:

Ube, JP (2016 - 2024)
Yamaguchi, JP (2019 - 2024)

Company Filing History:

University System of Maryland

patents

4. 3 out of 222

National Cancer Center

patents

5. 3 out of 3

Noile-Immune Biotech, Inc.

National University Corporation Totori University

patent

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2025-10-21),

2. 12129291 - Anti-GPC3 antibody (2024-10-29),

3. 12005103 - Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer (2024-06-11),

4. 11931381 - Immunocompetent cell and expression vector expressing regulatory factors of immune function (2024-03-19),

5. 11759518 - Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2023-09-19),

6. 11718663 - Anti-GPC3 antibody (2023-08-08),

7. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same (2023-04-04),

8. 11617765 - Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cells (2023-04-04),

9. 11491204 - Composition comprising poly I:C and LAG-3-IGG fusion protein (2022-11-08),

10. 11337997 - Immunocompetent cell and expression vector expressing regulatory factors of immune function (2022-05-24),

11. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

12. 11291718 - Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2022-04-05),

13. 10973893 - Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer (2021-04-13),

14. 10906984 - CAR expression vector and CAR-expressing T cells (2021-02-02),

15. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

Title: Innovations and Contributions of Koji Tamada in Cancer Immunotherapy

Introduction: Koji Tamada, an accomplished inventor based in Yamaguchi, Japan, has made significant strides in the field of cancer immunotherapy through his innovative research and development of antibodies. With a remarkable portfolio of 20 patents, his work primarily focuses on the identification and application of specific antibodies that enhance the detection and treatment of cancer.

Latest Patents: Among his latest patents, the most notable is the development of an anti-GPC3 antibody. This invention provides an anti-GPC3 antibody that recognizes an epitope distinct from that of existing antibodies, such as GC33 and GC199. The antibody can specifically bind to GPC3 localized on the cell membrane, even in the form of a single-chain antibody. Additionally, his patent includes a CAR (Chimeric Antigen Receptor) comprising this single-chain antibody, which is pivotal for generating immunocompetent cells expressing the CAR. These cells have significant implications for targeted cancer immunotherapy. He has also developed a method for specifically detecting GPC3 and a kit designed for its detection. Furthermore, Tamada's patents include the creation of immunocompetent cells that express regulatory factors of immune function, designed to enhance T cell responses against cancer antigens, thus showcasing his dedication to advancing cancer treatment options.

Career Highlights: Koji Tamada has worked with prestigious organizations such as Cytlimic Inc. and Yamaguchi University, where he contributed to groundbreaking research in immunotherapy. His diverse experience has allowed him to engineer innovative solutions that address critical healthcare challenges, particularly in oncology.

Collaborations: Throughout his career, Tamada has collaborated with notable colleagues, including Tomoya Miyakawa and Yukimi Sakoda. These partnerships have facilitated the exchange of ideas and expertise, further enriching his contributions to cancer research and the advancement of immunotherapeutic technologies.

Conclusion: Koji Tamada's innovative work in antibody development, particularly in the context of cancer immunotherapy, positions him as a leading figure in the scientific community. His patents not only reflect his dedication to enhancing cancer treatment but also illustrate the importance of collaborative efforts in scientific advancements. Through his contributions, Tamada continues to pave the way for future innovations in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.